Seroconversion among rituximab-treated patients following SARS-CoV-2 vaccine supplemental dose.
Autoimmune diseases
B cells
COVID-19
Hypogammaglobinemia
Rituximab
Vaccination
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
18
09
2022
accepted:
04
10
2022
pubmed:
12
10
2022
medline:
26
11
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
Rituximab (RTX) is a very effective treatment for autoimmune rheumatic diseases (AIRD), but it increases infection risk and impairs vaccine responses. Herein we evaluated the antibody response of RTX-treated patients to the supplemental COVID-19 vaccine. After the supplemental dose, 53.1% of patients had detectable antibody titers. Only 36% of patients who did not mount an antibody response after the original vaccine series did have detectable antibodies after the supplemental dose (seroconversion). Patients with undetectable CD20
Identifiants
pubmed: 36220613
pii: S1521-6616(22)00225-X
doi: 10.1016/j.clim.2022.109144
pmc: PMC9547394
pii:
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
COVID-19 Vaccines
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109144Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Lancet Rheumatol. 2022 Jan;4(1):e33-e41
pubmed: 34806036
Rheumatol Int. 2021 Jun;41(6):1115-1124
pubmed: 33811499
Ann Intern Med. 2021 Nov;174(11):1572-1585
pubmed: 34461029
Leuk Lymphoma. 2009 Mar;50(3):357-65
pubmed: 19263297
Vaccines (Basel). 2022 Apr 22;10(5):
pubmed: 35632424
Immunity. 2021 Sep 14;54(9):2133-2142.e3
pubmed: 34453880
Clin Immunol. 2022 Jan;234:108897
pubmed: 34848357
Ann Rheum Dis. 2021 Oct;80(10):1330-1338
pubmed: 34127481
Ann Rheum Dis. 2021 Oct;80(10):1345-1350
pubmed: 34285048
Lancet Rheumatol. 2021 Nov;3(11):e789-e797
pubmed: 34514436
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Ann Hematol. 2021 Nov;100(11):2805-2812
pubmed: 34549309
Arthritis Rheumatol. 2022 May;74(5):766-775
pubmed: 34807517
Am J Transplant. 2006 May;6(5 Pt 1):859-66
pubmed: 16611321
RMD Open. 2022 Apr;8(1):
pubmed: 35383121
Ann Rheum Dis. 2021 Oct;80(10):1357-1359
pubmed: 33975857
MMWR Morb Mortal Wkly Rep. 2021 Dec 17;70(50):1735-1739
pubmed: 34914672
Arthritis Rheumatol. 2019 Nov;71(11):1812-1823
pubmed: 31131994
J Clin Oncol. 1998 Aug;16(8):2825-33
pubmed: 9704735
Lancet Rheumatol. 2022 Mar;4(3):e177-e187
pubmed: 34977602